Should I buy or sell Iradimed stock right now?

1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IRMD shares. View IRMD analyst ratings or view top-rated stocks .

What is Iradimed's stock price target for 2024?

1 brokerages have issued 12-month target prices for Iradimed's shares. Their IRMD share price targets range from $60.00 to $60.00. On average, they expect the company's stock price to reach $60.00 in the next year. This suggests a possible upside of 46.8% from the stock's current price. View analysts price targets for IRMD or view top-rated stocks among Wall Street analysts .

How have IRMD shares performed in 2024?

Iradimed's stock was trading at $47.47 at the beginning of the year. Since then, IRMD stock has decreased by 13.9% and is now trading at $40.88. View the best growth stocks for 2024 here .

When is Iradimed's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our IRMD earnings forecast .

How were Iradimed's earnings last quarter?

Iradimed Corporation (NASDAQ:IRMD) announced its quarterly earnings data on Thursday, February, 8th. The medical equipment provider reported $0.36 EPS for the quarter, missing the consensus estimate of $0.37 by $0.01. The medical equipment provider had revenue of $17.45 million for the quarter. Iradimed had a trailing twelve-month return on equity of 24.62% and a net margin of 26.22%.

How often does Iradimed pay dividends? What is the dividend yield for Iradimed?

Iradimed announced a -- dividend on Tuesday, December 12th. Shareholders of record on Friday, December 22nd will be paid a dividend of $0.15 per share on Friday, January 12th. The ex-dividend date is Thursday, December 21st. Read our dividend analysis for IRMD .

Is Iradimed a good dividend stock?

Iradimed (NASDAQ:IRMD) pays an annual dividend of $0.60 per share and currently has a dividend yield of 1.45%. The dividend payout ratio is 44.12%. This payout ratio is at a healthy, sustainable level, below 75%. Read our dividend analysis for IRMD .

What ETF holds Iradimed's stock?

Ballast Small/Mid Cap ETF holds 29,988 shares of IRMD stock, representing 0.90% of its portfolio.

What guidance has Iradimed issued on next quarter's earnings?

Iradimed issued an update on its first quarter 2024 earnings guidance on Thursday, February, 8th. The company provided EPS guidance of 0.330-0.350 for the period, compared to the consensus EPS estimate of 0.410. The company issued revenue guidance of $17.0 million-$17.3 million, compared to the consensus revenue estimate of $17.6 million.

What other stocks do shareholders of Iradimed own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Iradimed investors own include NVIDIA (NVDA) , Gilead Sciences (GILD) , Alphabet (GOOG) , Mastercard (MA) , Micron Technology (MU) , PayPal (PYPL) , CRISPR Therapeutics (CRSP) , IntriCon (IIN) , QUALCOMM (QCOM) and Twitter (TWTR) .

Who are Iradimed's major shareholders?

Iradimed's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.39%) and Bridge City Capital LLC (0.33%). Insiders that own company stock include Anthony Vuoto , Christopher K Scott , James B Hawkins , Monty K Allen, Monty K Allen and Roger E Susi . View institutional ownership trends .

How do I buy shares of Iradimed?

Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

Positive News SentimentPositive News

NASDAQ:IRMD

Iradimed (IRMD) Stock Price, News & Analysis

→ Can't believe it's happening again (From Manward Press) (Ad)

Free IRMD Stock Alerts

$41.30

+0.42 (+1.03%)

(As of 12:07 PM ET)

Compare

Today's Range: $40.48
▼
$41.31
50-Day Range: $40.88
▼
$46.76
52-Week Range: $36.12
▼
$51.04

Volume: 8,309 shs
Average Volume: 52,031 shs
Market Capitalization: $522.86 million

P/E Ratio: 30.37
Dividend Yield: 1.45%
Price Target: $60.00

Get Iradimed alerts:

Iradimed MarketRank™ Stock Analysis

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 46.8% Upside
$60.00 Price Target
Short Interest: Healthy
1.36% of Float Sold Short
Dividend Strength: Weak
Based on Four Factors
Sustainability: -0.85
Upright™ Environmental Score
News Sentiment: N/A
Insider Trading: N/A
Proj. Earnings Growth: N/A

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.90 out of 5 stars

Medical Sector

19th out of 928 stocks

Surgical & Medical Instruments Industry

3rd out of 99 stocks

3.5

Analyst's Opinion

Consensus Rating
Iradimed has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Amount of Analyst Coverage
Iradimed has only been the subject of 1 research reports in the past 90 days.

4.0

Short Interest

Percentage of Shares Shorted
1.36% of the float of Iradimed has been sold short.
Short Interest Ratio / Days to Cover
Iradimed has a short interest ratio ("days to cover") of 2, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Iradimed has recently decreased by 3.99%, indicating that investor sentiment is improving.

1.7

Dividend Strength

Dividend Yield
Iradimed pays a meaningful dividend of 1.45%, higher than the bottom 25% of all stocks that pay dividends.
Dividend Growth
Iradimed does not have a long track record of dividend growth.
Dividend Coverage
The dividend payout ratio of Iradimed is 44.12%. This payout ratio is at a healthy, sustainable level, below 75%.

4.4

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Iradimed has received a 67.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is false driven by its "Real-time vital parameter monitors for MRI machines", "Intravenous therapy equipment for MRI machines", and "ECG monitors" products. See details.
Environmental Sustainability
The Environmental Impact score for Iradimed is -0.85.

3.8

News and Social Media Coverage

News Sentiment
Iradimed has a news sentiment score of 1.89. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.66 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for Iradimed this week, compared to 1 article on an average week.
Search Interest
9 people have searched for IRMD on MarketBeat in the last 30 days.
MarketBeat Follows
1 people have added Iradimed to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Iradimed insiders have not sold or bought any company stock.
Percentage Held by Insiders
42.60% of the stock of Iradimed is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
92.34% of the stock of Iradimed is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of Iradimed is 30.06, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 132.07.
Price to Earnings Ratio vs. Sector
The P/E ratio of Iradimed is 30.06, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 166.67.
Price to Book Value per Share Ratio
Iradimed has a P/B Ratio of 7.22. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Manward Press

Can't believe it's happening again

One of the single most unique and powerful events in the markets is coming in the next two months. It’s scheduled for April 22, 2024. But investors are moving now to get ahead of what’s coming… driving up prices of one asset dramatically. And you should do the same.

We explain how this event works in full right here.

About Iradimed Stock (NASDAQ:IRMD)

IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible medical devices and related accessories, and disposables and services in the United States and internationally. It offers MRidium MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets; MRI compatible patient vital signs monitoring system; and 3600 FMD1 with RALU ferromagnetic detection device. The company also provides non-magnetic IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories. It serves hospitals, acute care facilities, and outpatient imaging centers. The company sells its products through direct field sales representatives, regional sales directors, clinical application specialists, and independent distributors. IRADIMED CORPORATION was incorporated in 1992 and is headquartered in Winter Springs, Florida.

IRMD Stock Price History

30 days | 90 days | 365 days | Advanced Chart

IRMD Stock News Headlines

March 15, 2024 | finance.yahoo.com

IRMD Jul 2024 60.000 call

March 13, 2024 | globenewswire.com

IRADIMED CORPORATION To Participate at the 36th Annual Roth Conference

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

March 13, 2024 | wsj.com

iRadimed Corp.

February 26, 2024 | finance.yahoo.com

Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

February 26, 2024 | finance.yahoo.com

Calculating The Intrinsic Value Of IRadimed Corporation (NASDAQ:IRMD)

February 19, 2024 | finance.yahoo.com

Should You Invest in IRadimed Corporation (IRMD)?

February 17, 2024 | finance.yahoo.com

IRMD Mar 2024 45.000 put

April 16, 2024 | Manward Press (Ad)

Can't believe it's happening again

February 17, 2024 | finance.yahoo.com

IRMD Mar 2024 40.000 call

February 15, 2024 | finance.yahoo.com

IRMD Feb 2024 44.520 call

February 11, 2024 | finance.yahoo.com

Institutional investors own a significant stake of 39% in IRadimed Corporation (NASDAQ:IRMD)

February 9, 2024 | finance.yahoo.com

IRadimed Corporation (NASDAQ:IRMD) Q4 2023 Earnings Call Transcript

February 8, 2024 | finance.yahoo.com

iRadimed Corp (IRMD) Reports Record Revenues and Robust Earnings Growth in Q4 and Full-Year 2023

February 8, 2024 | markets.businessinsider.com

IRADIMED CORPORATION Announces Fourth Quarter of 2023 and Full Year of 2023 Financial Results

February 8, 2024 | washingtonpost.com

IRadimed: Q4 Earnings Snapshot

February 7, 2024 | benzinga.com

iRadimed's Earnings Outlook

February 7, 2024 | msn.com

iRadimed Q4 2023 Earnings Preview

February 7, 2024 | markets.businessinsider.com

Lake Street Reaffirms Their Buy Rating on Iradimed (IRMD)

February 1, 2024 | finance.yahoo.com

IRADIMED CORPORATION to Hold 2023 Fourth Quarter Financial Results Conference Call on February 8th.

February 1, 2024 | seekingalpha.com

IRadimed: Caution On The Valuation Of This Excellent Company

January 9, 2024 | finance.yahoo.com

IRADIMED CORPORATION Reports Unaudited Fourth Quarter and 2023 Revenue

January 7, 2024 | finance.yahoo.com

What Is IRadimed Corporation's (NASDAQ:IRMD) Share Price Doing?

January 2, 2024 | finance.yahoo.com

IRADIMED CORPORATION To Present at the 42nd Annual J.P. Morgan Healthcare Conference

December 18, 2023 | benzinga.com

Wednesday Is Your Last Chance To Buy iRadimed Before The Dividend Payout

December 12, 2023 | marketwatch.com

IRadimed Initiates 15c Quarterly Dividend, Declares Special Dividend of 48c

December 12, 2023 | finance.yahoo.com

IRADIMED CORPORATION Announces Establishment of a Quarterly Dividend of $0.15 per share and a Special Cash Dividend of $0.48 per share

See More Headlines

Receive IRMD Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Iradimed and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/08/2024
Today: 4/16/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Surgical & medical instruments
Sub-Industry: N/A
Current Symbol: NASDAQ:IRMD
CUSIP: N/A
CIK: 1325618
Web: www.iradimed.com
Phone: (407) 677-8022
Fax: 407-677-5037
Employees: 148
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $60.00
High Stock Price Target: $60.00
Low Stock Price Target: $60.00
Potential Upside/Downside: +46.8%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): $1.36
Trailing P/E Ratio: 30.06
Forward P/E Ratio: 30.28
P/E Growth: N/A
Net Income: $17.19 million
Net Margins: 26.22%
Pretax Margin: 33.16%
Return on Equity: 24.62%
Return on Assets: 20.43%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.65
Quick Ratio: 3.87

Sales & Book Value

Annual Sales: $65.56 million
Price / Sales: 7.89
Cash Flow: $1.41 per share
Price / Cash Flow: 28.99
Book Value: $5.66 per share
Price / Book: 7.22

Miscellaneous

Outstanding Shares: 12,660,000
Free Float: 7,269,000
Market Cap: $517.54 million
Optionable: Optionable
Beta: 0.82

10 "Recession Proof" Stocks That Will Thrive in Any Market

Which stocks are likely to thrive in today's challenging market? Click the link below and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.

Get This Free Report

Key Executives

Mr. Roger E. Susi (Age 71)
Founder, Chairman, CEO & President
Comp: $586.04k
Mr. John F. Glenn (Age 62)
CFO & Corporate Secretary
Comp: $411.79k
Mr. Randy Waddell
Vice President of Worldwide Sales & Marketing
Mr. Steve Kachelmeyer
Vice President of Regulatory Affairs & Quality Assurance
Mr. Lynn Neuhardt
Vice President of Research & Development
Mr. Chris Williamson
Executive Vice President of Continuous Improvement & Information Technology
Mr. Matt Garner
Controller

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

IRMD Stock Analysis - Frequently Asked Questions

Should I buy or sell Iradimed stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Iradimed in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" IRMD shares.
View IRMD analyst ratings or view top-rated stocks.
What is Iradimed's stock price target for 2024?: 1 brokerages have issued 12-month target prices for Iradimed's shares. Their IRMD share price targets range from $60.00 to $60.00. On average, they expect the company's stock price to reach $60.00 in the next year. This suggests a possible upside of 46.8% from the stock's current price.
View analysts price targets for IRMD or view top-rated stocks among Wall Street analysts.
How have IRMD shares performed in 2024?: Iradimed's stock was trading at $47.47 at the beginning of the year. Since then, IRMD stock has decreased by 13.9% and is now trading at $40.88.
View the best growth stocks for 2024 here.
When is Iradimed's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our IRMD earnings forecast.
How were Iradimed's earnings last quarter?: Iradimed Corporation (NASDAQ:IRMD) announced its quarterly earnings data on Thursday, February, 8th. The medical equipment provider reported $0.36 EPS for the quarter, missing the consensus estimate of $0.37 by $0.01. The medical equipment provider had revenue of $17.45 million for the quarter. Iradimed had a trailing twelve-month return on equity of 24.62% and a net margin of 26.22%.
How often does Iradimed pay dividends? What is the dividend yield for Iradimed?: Iradimed announced a -- dividend on Tuesday, December 12th. Shareholders of record on Friday, December 22nd will be paid a dividend of $0.15 per share on Friday, January 12th. The ex-dividend date is Thursday, December 21st.
Read our dividend analysis for IRMD.

Is Iradimed a good dividend stock?: Iradimed (NASDAQ:IRMD) pays an annual dividend of $0.60 per share and currently has a dividend yield of 1.45%. The dividend payout ratio is 44.12%. This payout ratio is at a healthy, sustainable level, below 75%.
Read our dividend analysis for IRMD.
What ETF holds Iradimed's stock?: Ballast Small/Mid Cap ETF holds 29,988 shares of IRMD stock, representing 0.90% of its portfolio.
What guidance has Iradimed issued on next quarter's earnings?: Iradimed issued an update on its first quarter 2024 earnings guidance on Thursday, February, 8th. The company provided EPS guidance of 0.330-0.350 for the period, compared to the consensus EPS estimate of 0.410. The company issued revenue guidance of $17.0 million-$17.3 million, compared to the consensus revenue estimate of $17.6 million.
What other stocks do shareholders of Iradimed own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Iradimed investors own include NVIDIA (NVDA), Gilead Sciences (GILD), Alphabet (GOOG), Mastercard (MA), Micron Technology (MU), PayPal (PYPL), CRISPR Therapeutics (CRSP), IntriCon (IIN), QUALCOMM (QCOM) and Twitter (TWTR).
Who are Iradimed's major shareholders?: Iradimed's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include Los Angeles Capital Management LLC (0.39%) and Bridge City Capital LLC (0.33%). Insiders that own company stock include Anthony Vuoto, Christopher K Scott, James B Hawkins, Monty K Allen, Monty K Allen and Roger E Susi.
View institutional ownership trends.
How do I buy shares of Iradimed?: Shares of IRMD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:IRMD) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial

Iradimed (IRMD) Stock Price, News & Analysis

Iradimed MarketRank™ Stock Analysis

Overall MarketRank™

Analyst's Opinion

Short Interest

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Change versus previous month

Dividend Strength

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score

Environmental Sustainability

News and Social Media Coverage

News Sentiment

News Coverage This Week

Search Interest

MarketBeat Follows

Company Ownership

Earnings and Valuation

About Iradimed Stock (NASDAQ:IRMD)

IRMD Stock Price History

IRMD Stock News Headlines

Company Calendar

Industry, Sector and Symbol

Price Target and Rating

Profitability

Debt

Sales & Book Value

Miscellaneous

Key Executives

Key Competitors

Insiders & Institutions

IRMD Stock Analysis - Frequently Asked Questions

Overall MarketRank^™